Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications
- 1 July 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600061
Abstract
Breast cancer is increasingly recognized as an obesity-associated disease, with obesity linked to higher risk of postmenopausal estrogen receptor–positive disease and adverse outcomes across stages. Adipose tissue dysfunction in chronic energy excess drives a tumor-supportive milieu: Crown-like structures and macrophage inflammation increase local aromatase and estrogen production, while elevated free fatty acids contribute to hyperinsulinemia and IGF-1 signaling with activation of PI3K/Akt/mTOR and MAPK pathways; leptin is increased and adiponectin reduced, amplifying proliferative and inflammatory cues. Standard breast cancer therapies can further worsen weight gain and insulin resistance, increasing symptom burden, reducing quality of life, and potentially compromising treatment delivery. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective agents for obesity and type 2 diabetes that improve glycemic control and reduce cardiovascular risk, prompting growing use in patients with breast cancer. Available breast cancer–specific data are largely retrospective and suggest clinically meaningful but attenuated weight loss compared with pivotal obesity trials, with concurrent aromatase inhibitor or tamoxifen use associated with smaller reductions. No unique breast cancer toxicities have been identified to date, to our knowledge, but clinicians should monitor GI tolerability, hydration and nutrition, and changes in body composition, including potential lean mass loss that may be mitigated with resistance training and adequate protein intake. Clinical considerations include changes in breast imaging during rapid weight loss (including possible increases in mammographic density), uncertainty regarding perioperative use in reconstructive surgery, and careful attribution of GI symptoms to GLP-1RA therapy versus chemotherapy. Studies also suggest potential survivorship benefits relevant to lymphedema and cardio-oncology, although causality is unproven. Prospective cancer-specific trials and implementation studies are needed to define safety; optimal timing; patient selection; and effects on oncologic outcomes, function, and quality of life.Keywords
This publication has 113 references indexed in Scilit:
- Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor AgonistsJAMA, 2025
- Current and Future Medications for Obesity TreatmentJAMA, 2025
- Achieving Healthy Weights for Improving Breast Cancer PrognosisJAMA Oncology, 2025
- Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the USJAMA, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast CancerJAMA Oncology, 2020
- Effect of Home-Based Exercise and Weight Loss Programs on Breast Cancer–Related Lymphedema Outcomes Among Overweight Breast Cancer SurvivorsJAMA Oncology, 2019
- Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast CancerJAMA Oncology, 2018
- Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal CancerJAMA Oncology, 2017